Ashling Wahner

Second-line fruquintinib plus sintilimab improved PFS, ORR, and DOR outcomes vs everolimus or axitinib monotherapy in advanced/metastatic RCC.

David M. Swoboda, MD, discusses data with quizartinib in FLT3-negative AML from the QUIWI trial and the rationale for the QuANTUM-Wild trial.

Dostarlimab plus chemotherapy improved 24-month DOR rates vs placebo plus chemotherapy in patients with primary advanced or recurrent endometrial cancer.

BVAC-C was effective with a manageable safety profile when combined with durvalumab in patients with recurrent HPV-positive cervical cancer.

Treatment with pembrolizumab monotherapy was effective and well tolerated in pretreated patients with advanced clear cell gynecologic cancers.

A BLA has been accepted in China seeking the approval of tisotumab vedotin for metastatic cervical cancer that has progressed on or after systemic therapy.

The feasibility and safety of treatment with SAR443216 support the further investigation of this agent in patients with advanced HER2-positive tumors.

Neratinib-containing combinations are consistently effective across CNS end points in patients with HER2-positive breast cancer brain metastases.

Benefits were seen with abemaciclib/fulvestrant regardless of metastatic site in HER2-negative advanced breast cancer following prior CDK4/6 inhibition.

Treatment with sacituzumab govitecan was effective and tolerable in real-world patients with mTNBC who received the agent in later-line settings.

Treatment with liso-cel induced long-term CR/CRi rates and high uMRD rates in patients with CLL/SLL following progression on BTK inhibition and venetoclax.

Treatment with 177Lu-edotreotide significantly improved PFS and numerically increased OS vs SOC everolimus in grade 1 or 2 SSTR-positive GEP-NETs.

R. Lor Randall, MD, FACS, discusses the significance of the FDA approval of vimseltinib for patients with symptomatic TGCT.

Aditya Bardia, MD, MPH, FASCO, discusses how the FDA approval of T-DXd for HER2-low/-ultralow metastatic breast cancer has affected the treatment paradigm.

Katy Beckermann, MD, PhD, discusses key findings from a PRO analysis of tivozanib/nivolumab vs tivozanib alone in ICI-pretreated RCC.

The FDA has approved tislelizumab-jsgr plus chemotherapy for frontline use in adult patients with advanced esophageal squamous cell carcinoma and PD-L1 expression.

Regina Barragan-Carrillo, MD, discusses a study of RCC clinical trial availability and barriers to opening RCC clinical trials in lower-income countries.

Read a recap of the episodes of OncLive On Air that aired in February 2025.

Amandeep Salhotra, MD, discusses data that have demonstrated the anti-GVHD activity of post-transplant Orca-Q in patients with hematologic malignancies.

Sia Daneshmand, MD, discusses how TAR-200 addresses an unmet need for patients with BCG-unresponsive, high-risk NMIBC.

Cameron S. Bader, PhD, discusses findings from a study evaluating the prevalence of FOXP3 and Helios expression in Orca-T recipients.

The combination of nivolumab and ipilimumab is under priority review for the frontline treatment of patients with unresectable/metastatic MSI-H/dMMR CRC.

D. Ross Camidge, MD, PhD, discusses ways that ALK-positive NSCLC management has changed based on 5-year follow-up data with lorlatinib in the CROWN trial.

Claire Harrison, MD, FRCP, FRCPath, discusses research that may evolve the clinical use of JAK inhibitors and mutation-specific therapies in myelofibrosis.

The NCCN Guidelines for metastatic uveal melanoma now recommend HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant disease.

The combination of first-line avelumab and axitinib was effective and safe in a real-world analysis of patients with advanced RCC.

UGN-102 generated robust, durable responses in patients with low-grade, intermediate-risk NMIBC, in analyses of the phase 3 ENVISION and ATLAS studies.

The FDA has approved vimseltinib for the treatment of patients with tenosynovial giant cell tumor.

NKTR-255 combined with CD19-directed CAR T-cell therapy improved 6-month CR rates vs placebo in patients with relapsed/refractory large B-cell lymphoma.

Kathleen N. Moore, MD, MS, discusses ongoing trials of novel ADCs in ovarian cancer and the potential relevance of biomarker expression for these agents.